National Cancer Awareness Month
Message from Dr. Tom Koutsavlis, Vice-President, Research & Development, Purdue Pharma (Canada)
April is Cancer Awareness Month. According to the Canadian Cancer Society, cancer is the leading cause of death in Canada and is responsible for 30% of all deaths. What’s more, nearly 1 in 2 Canadians will be diagnosed with cancer. These are staggering statistics. If there is good news in any of this, it may be that the 5-year cancer survival rate has increased from 25% in the 1940s to 60% today (2006-2008).
This month is about raising our collective awareness about the prevalence and outcomes of cancer in our society. As a physician, I can’t help but consider the multitude of symptoms that may impact these patients’ quality of life as they live with, fight, and try to conquer their disease. Chemotherapy remains a common treatment for many types of cancer, but can cause side effects such as nausea and vomiting which negatively affect the lives of patients. Further, pain from cancer and cancer treatments is one of the most dreaded symptoms and should be actively managed to help improve patient outcomes.
Purdue Pharma (Canada) is committed to supporting cancer patients with medications to help manage their acute and delayed chemotherapy induced nausea and vomiting, and we believe in a research-driven approach to managing pain that may or may not include available prescriptions products in combination with other effective treatments. The reality is that managing cancer outcomes is not “one size fits all” and we are committed to finding solutions for cancer patients to treat and live with their chemotherapy induced nausea and vomiting and their pain.
Purdue Pharma (Canada) is keeping these patients at the forefront of our research and development and we are proud of the work we are already doing to increase their quality of life. There’s more work to be done, and we’re not stopping here.